Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2020 Earnings Results

Arrowhead Pharmaceuticals Misses on EPS — Stock Down 0.41%

This earnings report indicates that Arrowhead Pharmaceuticals faced challenges in the first quarter, particularly reflected in their EPS miss. The stock reacted slightly down by 0.41%, suggesting a cautious sentiment among investors. The lack of revenue details and guidance may contribute to uncertainty about the company's future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.03	N/A	-177.52%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Overall, management expressed caution regarding the current market conditions. They highlighted the need for strategic adjustments moving forward.

Management did not provide specific guidance for the upcoming quarters.

The company acknowledged challenges in meeting expectations.

Arrowhead Pharmaceuticals Misses on EPS — Stock Down 0.41%

Key numbers

Management commentary

Arrowhead Pharmaceuticals, Inc.

More earnings this week

Arrowhead Pharmaceuticals Misses on EPS — Stock Down 0.41%

Key numbers

Management commentary